【Adimmune Corp.】February 2026 Revenue NT$0.06 Billion (YoY -19.7%)
NQ Score
48/100
N1 Content Completeness
4
AI Summary (NQ-processed)
Adimmune Corporation (4142), a vaccine and biopharmaceutical developer and manufacturer, announced its February 2026 revenue. The company's monthly revenue was NT$0.06 billion, a 19.7% decrease compared to the same period last year. This figure reflects seasonal factors, as the peak flu vaccine shipping season has passed, leading to a traditional off-peak season for revenue.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What was Adimmune Corp.'s revenue for February 2026?
- A: Adimmune Corp.'s revenue for February 2026 was NT$5,849 Thousand, which is equivalent to NT$0.06 Billion.
- Q: How did Adimmune Corp.'s February 2026 revenue compare to the previous year?
- A: Adimmune Corp.'s revenue in February 2026 experienced a year-over-year decrease of 19.7%.
- Q: What is the company code for Adimmune Corp.?
- A: The company code for Adimmune Corp. is 4142.
- Q: In which industry does Adimmune Corp. operate?
- A: Adimmune Corp. operates within the Biotechnology and Medical Industry.
- Q: What was the specific monthly revenue figure for Adimmune Corp. in February 2026?
- A: The specific monthly revenue figure for Adimmune Corp. in February 2026 was NT$5,849 Thousand.